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Word count: 746 words 78 
Prompt identification of acute myocardial infarction (AMI) may be particularly challenging in 79 
patients with prior coronary artery bypass grafting (CABG). The impact of prior CABG on the 80 
diagnostic performance of high-sensitivity cardiac troponin (hs-cTnT/I) concentrations and the 81 
European Society of Cardiology (ESC) 0/1h-algorithms is unknown.  82 
To address this major gap in knowledge, we performed a secondary analysis from a prospective 83 
international multicentre study enrolling adult patients presenting to the emergency department 84 
with symptoms suggestive of AMI (ClinicalTrials.gov registry, NCT00470587).(1) Patients on 85 
chronic dialysis, an unknown diagnosis after final adjudication and at least one elevated hs-86 
cTnT level possibly indicating AMI, as well as patients with chest pain onset or peak >12 hours 87 
before presentation were excluded. According to the intended use, patients with ST-segment 88 
elevation myocardial infarction (STEMI) were excluded when analyzing the diagnostic 89 
performance of the ESC 0/1h-algorithms.(2,3) Final diagnoses were adjudicated by two 90 
independent cardiologists applying the fourth universal definition of AMI using all available 91 
medical records, cardiac imaging information, as well as study-specific assessments.(4)  92 
Overall, 4015 patients were prospectively enrolled and eligible for the analysis of AMI 93 
prevalence. Of these, 3860 patients qualified for the analysis of the diagnostic performance of 94 
hs-cTnT/I concentrations, and 3054 patients for analysis of the hs-cTnT ESC 0/1h-algorithm. 95 
Patients with prior CABG were older, more often men, more often had prior AMI and known 96 
peripheral vascular disease, prior percutaneous coronary intervention, and known 97 
cardiovascular risk factors. The prevalence of AMI was significantly higher in patients with 98 
previous CABG (35% versus 18%; p<0.001). Patients with prior CABG had significantly 99 
higher concentrations of hs-cTnT/I at presentation compared to patients without previous 100 
CABG (e.g. hs-cTnT median (IQR) 19 (11, 42) ng/L versus 8 (4, 19) ng/L, p<0.001), which 101 
was exclusively due to higher concentrations in patients with final diagnoses other than AMI 102 
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including heart failure and rhythm disorders (e.g. hs-cTnT median (IQR) 13 (9, 23) versus 6 (4, 103 
11) ng/L; p<0.001). Patients with AMI had much higher hs-cTnT/I concentrations as compared 104 
to those with other final diagnoses, irrespective of prior CABG. The size of the index AMI as 105 
quantified by peak local cTnT/I concentrations and peak study-specific hs-cTnT/I 106 
concentrations was smaller in patients with prior CABG as compared to those without prior 107 
CABG (e.g. hs-cTnT/99th percentile median (IQR) ratio 5.2 (2.6, 13.6) versus 7.4 (3.2, 20.9), 108 
p=0.006), which might possibly be related to the increased collateral flow provided by the 109 
bypass grafts. 110 
The diagnostic accuracy of hs-cTnT/I concentrations at presentation was high in patients with 111 
prior CABG, but significantly lower compared to patients without prior CABG (hs-cTnT: AUC 112 
0.87 [95%CI 0.82-0.91] versus AUC 0.94 [95%CI 0.93-0.95], p=0.001; hs-cTnI: AUC 0.85 113 
[95%CI 0.81-0.89] versus AUC 0.94 [95%CI 0.93-0.95]; p<0.001). In patients with prior 114 
CABG, the ESC hs-cTnT 0/1h-algorithm maintained very high negative predictive value (100 115 
(94.6-100)%) and high positive predictive value (90.6 (81.0-95.6)%), but had lower efficacy 116 
with more patients remaining in the observe zone (50% versus 21% compared to patients 117 
without prior CABG; p<0.001). Given the high percentage of patients with prior CABG 118 
remaining in the observe zone, it is important to highlight the critical importance of detailed 119 
clinical assessment, hs-cTn re-sampling at 3h, transthoracic echocardiography, and often also 120 
coronary angiography in this subgroup of patients. 121 
In conclusion, history of CABG substantially impacts on AMI incidence and the diagnostic 122 
accuracy of hs-cTnT/I, while the safety of the hs-cTnT ESC 0/1h-algorithm remains very high.  123 
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Figure Legend 138 
Figure 1. Diagnostic performance of hs-cTn and the ESC hs-cTnT 0/1h-algorithm 139 
Diagnostic accuracy of hs-cTnT/I concentrations at presentation for the diagnosis of AMI 140 
according to the presence or absence of prior CABG (A). Diagnostic performance of the ESC 141 
hs-cTnT 0/1h-algorithm in patients with prior CABG (B). 142 
 143 
NSTEMI – Non-ST-elevation myocardial infarction 144 
Sens. – Sensitivity 145 
Spec. – Specificity 146 
NPV – negative predictive value,  147 
PPV – positive predictive value,  148 
hs-cTnT/I – high-sensitivity cardiac troponin T/I 149 
* if chest pain onset >3h 150 
 151 
 152 
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